Pharma: GSK stops research on cough medicine

—·3h

GSK PLc is ending development of the chronic cough drug Camlipixant after mixed study results. Investors react with disappointment and the shares lose significant value.

TickersGSK, PLChannelssemiconductors, stocksCountriesgermany, europeCategoriesearnings

Open original source ↗

Published

7/17/2026, 6:56:00 PM

Fetched

7/17/2026, 9:07:21 PM

Confidence

60 / 100

Relevance

42 / 100

Trust

—

Language